@article{7e6381e7b06a43dea635d38c744215a2,
title = "Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome",
abstract = "There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.",
keywords = "COVID-19, SARS-CoV-2, convalescent plasma, pediatrics",
author = "Caroline Diorio and Anderson, {Elizabeth M.} and McNerney, {Kevin O.} and Goodwin, {Eileen C.} and Chase, {Julie C.} and Bolton, {Marcus J.} and Arevalo, {Claudia P.} and Weirick, {Madison E.} and Sigrid Gouma and Vella, {Laura A.} and Henrickson, {Sarah E.} and Kathleen Chiotos and Fitzgerald, {Julie C.} and Kilbaugh, {Todd J.} and John, {Audrey R.Odom} and Blatz, {Allison M.} and Lambert, {Michele P.} and Sullivan, {Kathleen E.} and Tartaglione, {Margaret R.} and Danielle Zambrano and Meghan Martin and Lee, {Jessica H.} and Pampee Young and David Friedman and Sesok-Pizzini, {Deborah A.} and Hensley, {Scott E.} and Behrens, {Edward M.} and Hamid Bassiri and Teachey, {David T.}",
note = "Funding Information: Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team (David T. Teachey, Edward M. Behrens, Hamid Bassiri), National Institute of Allergy and Infectious Diseases (NIAID) (US): R01AI121250 (Edward M. Behrens), R01AI103280 (Audrey R. Odom John), R01AI123433 (Audrey R. Odom John), R21AI144472 (Audrey R. Odom John), K08 AI136660 (Laura A. Vella), and K08AI135091 (Sarah Henrickson); Agency for Healthcare Research and Quality (AHRQ): 5K12HS026393 (Kathleen Chiotos); National Cancer Institute (NCI) (US): R01CA193776 (David T. Teachey), X01HD100702‐01 (David T. Teachey), 5UG1CA233249 (David T. Teachey), and R01A1123538 (David T. Teachey); NIH Training in Virology: T32‐AI‐007324 (Elizabeth M. Anderson); Leukemia and Lymphoma Society (David T. Teachey); Cookies for Kids Cancer (David T. Teachey); Alex's Lemonade Stand Foundation for Childhood Cancer (David T. Teachey); Children's Oncology Group (David T. Teachey); Stand UP 2 Cancer (David T. Teachey); Team Connor (Hamid Bassiri); and Kate Amato Foundations (Hamid Bassiri). Burroughs Wellcome Fund CAMS (SH) and PATH (Audrey R. Odom John); Clinical Immunology Society (SH); and American Academy of Allergy, Asthma, and Immunology (SH). Serological studies were supported by institutional funds from the University of Pennsylvania. Caroline Diorio was supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania. We gratefully acknowledge the gift of plasmids of the receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein from Florian Krammer, Mt. Sinai, and the gift of the RBD‐specific monoclonal antibody CR3022 from Ian Wilson, Scripps Research Institute. We gratefully acknowledge the providers who cared for these patients, and the generosity of the patients and their families. Funding Information: Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team (David T. Teachey, Edward M. Behrens, Hamid Bassiri), National Institute of Allergy and Infectious Diseases (NIAID) (US): R01AI121250 (Edward M. Behrens), R01AI103280 (Audrey R. Odom John), R01AI123433 (Audrey R. Odom John), R21AI144472 (Audrey R. Odom John), K08 AI136660 (Laura A. Vella), and K08AI135091 (Sarah Henrickson); Agency for Healthcare Research and Quality (AHRQ): 5K12HS026393 (Kathleen Chiotos); National Cancer Institute (NCI) (US): R01CA193776 (David T. Teachey), X01HD100702-01 (David T. Teachey), 5UG1CA233249 (David T. Teachey), and R01A1123538 (David T. Teachey); NIH Training in Virology: T32-AI-007324 (Elizabeth M. Anderson); Leukemia and Lymphoma Society (David T. Teachey); Cookies for Kids Cancer (David T. Teachey); Alex's Lemonade Stand Foundation for Childhood Cancer (David T. Teachey); Children's Oncology Group (David T. Teachey); Stand UP 2 Cancer (David T. Teachey); Team Connor (Hamid Bassiri); and Kate Amato Foundations (Hamid Bassiri). Burroughs Wellcome Fund CAMS (SH) and PATH (Audrey R. Odom John); Clinical Immunology Society (SH); and American Academy of Allergy, Asthma, and Immunology (SH). Serological studies were supported by institutional funds from the University of Pennsylvania. Caroline Diorio was supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania. We gratefully acknowledge the gift of plasmids of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein from Florian Krammer, Mt. Sinai, and the gift of the RBD-specific monoclonal antibody CR3022 from Ian Wilson, Scripps Research Institute. We gratefully acknowledge the providers who cared for these patients, and the generosity of the patients and their families. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",
year = "2020",
month = nov,
day = "1",
doi = "10.1002/pbc.28693",
language = "English (US)",
volume = "67",
journal = "Medical and Pediatric Oncology",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "11",
}